Evolent Health (EVH) Net Income towards Common Stockholders (2014 - 2026)

Evolent Health's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$26.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 63.14% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$533.8 million (down 279.97% YoY), while the FY2025 annual figure was -$579.4 million, down 519.99% from the prior year.
• Net Income towards Common Stockholders was -$26.6 million for Q1 2026 at Evolent Health, up from -$429.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $2.1 million in Q3 2022 to a low of -$429.1 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$50.6 million across 5 years, with a median of -$26.9 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 116.28% in 2022, then plunged 1663.64% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.3 million in 2022, then sank by 264.75% to -$41.4 million in 2023, then rose by 26.04% to -$30.6 million in 2024, then tumbled by 1301.7% to -$429.1 million in 2025, then surged by 93.79% to -$26.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$26.6 million (Q1 2026), -$429.1 million (Q4 2025), and -$26.9 million (Q3 2025), per Business Quant data.